2,869 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Aaron Wealth Advisors LLC

Aaron Wealth Advisors LLC purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 2,869 shares of the medical research company’s stock, valued at approximately $449,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brooklyn Investment Group grew its position in shares of Charles River Laboratories International by 93.5% in the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after buying an additional 86 shares during the last quarter. Cromwell Holdings LLC boosted its holdings in Charles River Laboratories International by 542.9% in the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 152 shares in the last quarter. Neo Ivy Capital Management purchased a new position in Charles River Laboratories International during the 2nd quarter valued at $29,000. Geneos Wealth Management Inc. increased its position in Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares during the period. Finally, Allworth Financial LP raised its holdings in Charles River Laboratories International by 172.7% in the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after purchasing an additional 190 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on CRL shares. Barclays lifted their target price on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. William Blair raised Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research report on Monday, October 6th. Mizuho raised their target price on Charles River Laboratories International from $174.00 to $200.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target on the stock in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $195.93.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $193.76 on Friday. The company has a market capitalization of $9.54 billion, a price-to-earnings ratio of -124.21, a price-to-earnings-growth ratio of 6.92 and a beta of 1.63. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $200.58. The company’s 50-day moving average is $179.24 and its 200 day moving average is $164.93.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. During the same quarter in the prior year, the firm posted $2.59 earnings per share. The business’s revenue was down .5% on a year-over-year basis. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).